acamprosate vs doxepin
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and doxepin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Sinequan, Silenor
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Doxepin is a medicine that can help you stay asleep. It belongs to a class of drugs called tricyclic antidepressants.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Doxepin is used to treat insomnia, which means you have trouble staying asleep. It can help you sleep better if you have problems with waking up during the night. This medicine has been tested for up to 3 months.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Doxepin works by affecting certain natural chemicals in the brain that help regulate sleep. It helps to keep you asleep throughout the night. It is a low dose formulation of a tricyclic antidepressant.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Feeling sleepy or drowsy
- • Feeling sick to your stomach
- • Upper respiratory tract infection (like a cold)
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Toxicity To Various Agents 801
- Completed Suicide 613
- Fatigue 599
- Nausea 557
- Pain 527
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
After taking doxepin, some people have done things like driving a car while not fully awake. You might not remember doing it. This can be dangerous, so tell your doctor right away if this happens. Doxepin may also worsen depression or cause suicidal thoughts. Tell your doctor if you notice any new or worsening symptoms of depression.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
Taking doxepin late in pregnancy may cause problems for the newborn baby, like trouble breathing or feeding. Breastfeeding is not recommended while taking this medicine.
Also Compare, Nearby Drugs
Compare doxepin with
How to Read This acamprosate vs doxepin Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while doxepin sits within the Tricyclic Antidepressant (TCA) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while doxepin has 3,097. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or doxepin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.